
Merlintrader Trading Pub
Biotech catalyst, news and analysis PDUFA tracker

Merlintrader Trading Pub
Biotech catalyst, news and analysis PDUFA tracker
AI transparency: articles and reports are produced with the help of artificial intelligence and checked through a process that does not constitute specialist validation. They may contain errors: verify relevant information with independent sources. Read the full disclaimer.
Nov 10, 2026, 11:09 AM ET
RBC Capital lifts Definium price target to $70, keeps Outperform rating
Nasdaq: $DFTXPsychiatric medicinesDT120 Phase 3 programRegulatory and dilution risk
DFTX Stock Hub: Definium Therapeutics News, DT120 and the FDA Filing Path
Positive pivotal findings now sit on a funded balance sheet and a 2027 filing window. Third-quarter results on November 9, 2026 reported $1,046.848 million of cash and investments at September 30 and a net loss of $51.0 million, with the company saying the balance funds operations into 2030. DT120 holds FDA Breakthrough Therapy designation in GAD and MDD, and the NDA filing is anticipated in H1 2027.
Full research report · PDF
Definium Therapeutics ($DFTX), research updated November 9, 2026
18 pages covering DT120 Phase 3 evidence, functional unblinding, safety, supervised-treatment economics, the September 30 accounts and regulatory milestones. This is dated research; the hub follows later developments. For personal use only: redistribution prohibited.
Next scheduled company appearance
November 17, 2026 · 11:30 a.m. GMT · Jefferies healthcare conference, London
On November 9, 2026, Definium reported a net loss of $51.0 million, or $(0.37) per share basic and $(0.46) diluted, on $72.279 million of operating expenses. Cash and investments were $1,046.848 million at September 30, 2026, and the company said the balance funds operations into 2030. Company release
Next on the regulatory path: an NDA filing anticipated in H1 2027 (third-quarter release) and, as stated in the September 14 Panorama release, a pre-NDA meeting with the FDA in Q4 2026; neither is an FDA decision date. The third-quarter release also reported initial Phase 2a results for DT402 in five adults with autism spectrum disorder, an exploratory open-label study not powered for statistical conclusions. A Stifel 2026 Healthcare Conference fireside chat was scheduled for November 10 at 9:20 a.m. ET; management then presents at Jefferies in London on November 17, Evercore on December 1 and Piper Sandler on December 2. Conference announcement
DFTX stock at a glance
Chart analysis · JC
Technical chart analysis of $DFTX with bull and bear scenarios on JC Just Charts.
Cash and investments · September 30
$1,046.848M
$241.150M of cash and $805.698M of short-term investments; company runway into 2030.
Operating cash use · nine months 2026
$148.389M
Nine months ended September 30, against $88.585M in the same period of 2025.
Net loss · third quarter
$51.0M
$(0.37) per share basic and $(0.46) diluted; $67.3M in the year-earlier quarter.
Basic share count · November 2
136.9M
136,899,935 shares on the quarterly-report cover; 98,776,265 at December 31, 2025.
Panorama Phase 3 population
245 participants
September 14 topline release; 100µg, 50µg and placebo groups.
Panorama HAM-A difference
5.1 points
Placebo-adjusted Week 12 difference at 100µg; nominal p<0.0001, reported d=0.64.
Where Definium Therapeutics stands now
DT120 has positive Phase 3 topline findings in GAD and MDD, Breakthrough Therapy designation in both indications and a funded balance sheet, but remains investigational. The September 30, 2026 accounts report $1,046.848 million of cash and investments and $148.389 million of operating cash use in the first nine months, and the company says the balance funds operations into 2030. The next evidence combines the registration package, long-term safety, MDD replication in Ascend and the economics of a supervised treatment model. September 30 accounts
Positive topline evidence is not proof of approval or commercial access. Functional unblinding, safety and retreatment, controlled-substance scheduling, monitoring capacity and reimbursement can change the benefit-risk and practical use of the treatment. Third-quarter research and development expense of $46.1 million and general and administrative expense of $26.1 million show the spending that precedes any revenue, and a larger share base changes per-share outcomes even when cash increases.
The constructive case
Three positive Phase 3 topline studies and Breakthrough Therapy designation in two indications give the programme a stronger starting package than one isolated readout. With $1,046.848 million at September 30 and runway language extending into 2030, development and regulatory preparation are funded if the complete dataset, safety and execution hold.
The cautious case
The complete regulatory assessment may differ from a topline interpretation. Spending is rising across both operating lines, the next clinical readout is Ascend in 2027 rather than an imminent one, and supervised dosing, site throughput, payer terms and long-term safety can constrain commercial economics.
Latest Definium Therapeutics news
Nov 13, 2026
Phase 2A DT402 autism trial status updated to completed
Definium Therapeutics US, Inc. updated the status of its Phase 2A trial of DT402 for Autism Spectrum Disorder (NCT07303907) to COMPLETED on ClinicalTrials.gov. The record update was posted 2026-11-13 and gives a completion date of 2026-09-16. The trial enrollment is listed as 5, with conditions Autism Spectrum Disorder and ASD.
Nov 10, 2026
RBC Capital lifts Definium price target to $70, keeps Outperform rating
RBC Capital raised its price target on Definium Therapeutics to $70 from $66 and kept its Outperform rating. Analyst action reported by the press; it is the bank's view, not Merlintrader's.
Nov 9, 2026
Definium Therapeutics reports third quarter 2026 financial results and recent highlights
Definium Therapeutics reported its third quarter 2026 financial results and recent highlights.
Nov 4, 2026
Definium Presents Topline Phase 3 DT120 ODT Data in Generalized Anxiety, Major Depressive Disorder
Definium Therapeutics presented topline Phase 3 data for DT120 ODT in generalized anxiety disorder and major depressive disorder at the 2026 NEI Fall Congress.
Nov 3, 2026
Definium Therapeutics to participate at upcoming investor conferences
Definium Therapeutics announced that it will participate at upcoming investor conferences. No further details were included in the headline.
Oct 29, 2026
Third-quarter results webcast scheduled for November 9
The webcast is scheduled for 4:30 p.m. EST to discuss the September quarter and business highlights. This announcement contains no new quarterly financial figures.
DFTX stock catalysts: results, the FDA filing path and MDD replication
- November 6–7, 2026 — NEI Fall Congress, Colorado Springs, as scheduled in the November 4 announcement: sponsored Scientific Exchange oral presentation on November 6 at 5:25–6:35 p.m. local time (7:25–8:35 p.m. ET); four posters on November 7 at 2:40–3:40 p.m. local time (4:40–5:40 p.m. ET) covering Panorama (first congress presentation), encore Emerge and Voyage topline data, and DT120 Phase 3 safety. Past congress dates; topline results already announced
- November 9, 2026 — Third-quarter results reported: net loss $51.0 million, $(0.37) per share basic and $(0.46) diluted, cash and investments $1,046.848 million at September 30. Reported
- November 10, 2026 · 9:20 a.m. ET — Fireside chat at the Stifel 2026 Healthcare Conference (New York); webcast. Past investor event
- November 17 and 19, 2026 — Jefferies Global Healthcare Conference in London: fireside chat on November 17 at 11:30 a.m. GMT (6:30 a.m. ET) and a psychedelics panel on November 19 at 10:30 a.m. GMT (5:30 a.m. ET). Scheduled investor event
- December 1 and 2, 2026 — Fireside chats at the 9th Annual Evercore Healthcare Conference (Coral Gables, December 1, 3:50 p.m. ET) and the Piper Sandler 38th Annual Healthcare Conference (New York, December 2, 4:00 p.m. ET). Scheduled investor events
- Q4 2026 — DT120 GAD pre-NDA meeting. Company window; not an approval
- H1 2027 — Anticipated GAD NDA filing. Company expectation
- 2027 — Ascend Phase 3 MDD topline, approximately 165 participants randomized 2:1:2, with safety and retreatment follow-up. Company expectation
- 2027 — Planned Phase 3 Haven study in PTSD, approximately 200 participants randomized 1:1, CAPS-5 at Week 8. Planned; not started
- 2027 — Planned DT402 study of multiple dosing paradigms. Planned
- H1 2027 — Planned first Commercial Day. Company plan
- September 15–19, 2026 — Psych Congress presentations. Past event
Third-quarter results, November 9 · Form 10-Q, September 30 · Investor-conference announcement, November 3 · NEI Fall Congress presentations, November 4 · Panorama and regulatory windows
DFTX DT120 evidence: replication and functional unblinding
Voyage and Panorama provide positive GAD topline findings, while Emerge supports the MDD program and drew Breakthrough Therapy designation in September 2026. Ascend, with approximately 165 participants randomized 2:1:2, addresses MDD replication and reports topline in 2027. Patients recognizing an active psychedelic dose, longer-term safety and durability remain relevant to interpretation and regulatory review. Outside DT120, DT402 reported initial Phase 2a results in five adults with autism spectrum disorder in November 2026; the open-label study was exploratory and not powered for statistical conclusions.
DFTX funding and the supervised-treatment model
June funding increased resources and shares at the same time. Cash and investments stood at $1,046.848 million on September 30, 2026, with 136,887,557 shares outstanding; third-quarter research and development expense of $46.1 million and general and administrative expense of $26.1 million show the ramp that precedes any revenue. Treatment-center capacity, monitoring time, controlled-substance scheduling and reimbursement determine whether a clinically effective supervised dose can become an accessible commercial service. September 30 accounts and risks
Merlintrader Health Score · $DFTX
3.9out of 5
Assessed November 9, 2026, after the third-quarter 2026 results. Weighted calculation: 4.5×30% + 4.0×30% + 2.5×20% + 4.0×10% + 4.0×10% = 3.85, rounded to 3.9. This describes financial and operational robustness over twelve to eighteen months, not an investment recommendation.
Red flags
- DT120 remains investigational; topline success is not regulatory approval.
- Functional unblinding and long-term retreatment safety remain material.
- Supervised dosing requires capacity, reimbursement and scheduling decisions.
- Operating expenses rose to $72.279 million in the third quarter from $45.669 million a year earlier.
- Cash, net financing proceeds and current shares are different measures.
DFTX Stock FAQ: Definium Therapeutics Questions Answered
What is the next Definium DFTX stock catalyst for DT120?
As of November 18, 2026, Definium’s next scheduled company appearances are fireside chats at Evercore (December 1) and Piper Sandler (December 2). Earlier fireside chats were set for November 10 (Stifel, 9:20 a.m. ET) and November 17 (Jefferies, London, 11:30 a.m. GMT). The next regulatory step for DT120 is a pre-NDA meeting with the FDA planned in Q4 2026 (September 14 Panorama release) and an NDA submission anticipated in H1 2027; neither is an FDA decision date. Ascend, the MDD replication study, reports topline in 2027, and the Phase 3 Haven study in PTSD is planned to start in 2027. Third-quarter results and recent highlights. Investor-conference schedule.
Is Definium DFTX’s DT120 FDA approved?
No. DT120 remains investigational as of November 9, 2026, with an NDA submission anticipated in H1 2027. The FDA has granted Breakthrough Therapy designation to the DT120 programme in GAD (March 2024) and in MDD (September 2026), which supports closer regulatory interaction but does not authorise commercial sales. FDA review, any approval conditions and controlled-substance requirements remain relevant to a possible launch. Company regulatory status and results.
How much cash does Definium DFTX have and what is its cash burn?
Definium held $1,046.848 million of cash, cash equivalents and investments on September 30, 2026, made up of $241.150 million of cash and equivalents and $805.698 million of short-term investments. Operating cash use was $148.389 million in the first nine months of 2026, against $88.585 million in the same period of 2025. Management said the September 30 balance is sufficient to fund operations into 2030. Quarterly liquidity and cash flows.
How did Definium DFTX’s June financing dilute shareholders?
Definium’s June 25, 2026 offering raised approximately $805 million gross and $757.9 million net by issuing common shares, including the fully exercised underwriters’ option. Shares outstanding rose from 98,776,265 at December 31, 2025 to 136,887,557 at September 30, 2026, and stood at 136,899,935 on November 2, 2026. Warrants, options and equity compensation can produce further dilution; gross proceeds are not the same as the amount added to usable cash. Share count and equity instruments.
When are Definium DFTX’s next earnings results?
Definium reported third-quarter 2026 results on November 9, 2026, with a net loss of $51.0 million and $1,046.848 million of cash and investments at September 30. As of November 11, 2026, the company had not announced a date for its fourth-quarter and full-year 2026 results. Third-quarter results release.
What does Definium Therapeutics DFTX do?
Definium Therapeutics develops treatments for psychiatric and neurological disorders. Its lead candidate, DT120 ODT, is an orally disintegrating formulation of lysergide being studied for anxiety, depression and other conditions. The company remains in clinical development, with a program designed to evaluate supervised dosing and the durability of patients’ responses. Company business and clinical programs.
What did Definium DFTX’s Panorama trial show for anxiety?
Definium’s September 14, 2026 Panorama announcement reported a placebo-adjusted 5.1-point improvement in HAM-A anxiety scores at week 12 for DT120 ODT 100 micrograms (p<0.0001). This was a generalized anxiety disorder trial. Depression is tested in separate Phase 3 studies: Emerge reported topline data in June 2026, and Ascend, a second trial in major depressive disorder, dosed its first patient in May 2026. Panorama topline results. Emerge and Ascend depression studies.
Primary sources
- November 9, 2026 · Third-quarter 2026 results and recent highlights
- November 9, 2026 · Form 8-K, exhibit 99.1: third-quarter results
- Form 10-Q for the quarter ended September 30, 2026
- November 4, 2026 · DT120 Phase 3 presentations at the 2026 NEI Fall Congress (November 6–7)
- November 3, 2026 · Investor conferences: Stifel, Jefferies London, Evercore and Piper Sandler
- October 29, 2026 · Third-quarter results webcast scheduled for November 9
- September 28, 2026 · Employee options create potential future issuance
- September 14, 2026 · Panorama meets primary and key secondary endpoints
- September 10, 2026 · Psych Congress presentations announced
- August 12, 2026 · Voyage provides positive Phase 3 GAD topline evidence
- June 25, 2026 · Upsized offering closes with full option exercise
- Form 10-Q for the quarter ended June 30, 2026
Disclaimer. This content is published by Merlintrader for educational and informational purposes only. It is independent journalism and research. It does not constitute investment advice, an investment recommendation, an offer or a solicitation to buy or sell any security, and it is not a research report within the meaning of applicable United States securities regulation. Nothing here should be read as a recommendation to buy, sell or hold $DFTX or any other security.
Figures are taken from public filings with the U.S. Securities and Exchange Commission, company press releases and market-data providers, and are stated with their reference dates. Data can change without notice, and figures published before a results release become outdated the moment that release is issued. Merlintrader makes no representation that the information is complete or current at the time of reading. Readers should verify every figure against the primary source before acting on it.
Biotechnology and healthcare companies carry binary risk. Clinical trials fail, regulatory decisions go against the applicant, approval does not guarantee commercial uptake, and development-stage companies frequently raise equity at whatever price the market will bear. A single readout can change the value of the business overnight in either direction, and companies at this stage can lose all of their value. Every reader is responsible for their own decisions and should consult a licensed financial adviser where appropriate.
Merlintrader may hold positions in securities mentioned. Some links on this page are affiliate or referral links, including those to Finviz and Stocktwits, which may generate a commission at no cost to the reader. Full legal information is available on the disclaimer and terms of use and privacy pages.



